Terapevticheskii arkhiv · 2006
[Optimization of hepatoprotective therapy of viral hepatitis with consideration of neuromediatory link of pathogenesis].
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sitnikov I G, Maleev V V, Shoshin A A
Аннотация
AIM: To study therapeutic efficacy of hepatoprotective modalities on the experimental hepatitis model and in patients with parenteral hepatitis B and C regarding neurogenic amines and their coefficients.
MATERIAL AND METHODS: 38 hepatoprotectors were screened for the highest activity in 1000 white rats with toxic hepatitis. Blood catecholamines (CA), histamine (H), serotonin (S), 11-oxycorticosteroids (11-OCS) were studied in 100 patients with acute hepatitis B and C.
RESULTS: The recommended hepatoprotectors optimized treatment of hepatitis, led to rapid correction of abdominal and dyspeptic syndromes, normalization of bilirubin, alkaline phosphatase, cytolysis enzymes levels, improvement of neuromediatory balance. Six-month follow-up demonstrated improvement of biochemical indices in patients given hepatoprotectors with a confirmed action.
CONCLUSION: Hepatoprotectors are necessary in pathogenetic treatment of acute hepatitis B and C.
MATERIAL AND METHODS: 38 hepatoprotectors were screened for the highest activity in 1000 white rats with toxic hepatitis. Blood catecholamines (CA), histamine (H), serotonin (S), 11-oxycorticosteroids (11-OCS) were studied in 100 patients with acute hepatitis B and C.
RESULTS: The recommended hepatoprotectors optimized treatment of hepatitis, led to rapid correction of abdominal and dyspeptic syndromes, normalization of bilirubin, alkaline phosphatase, cytolysis enzymes levels, improvement of neuromediatory balance. Six-month follow-up demonstrated improvement of biochemical indices in patients given hepatoprotectors with a confirmed action.
CONCLUSION: Hepatoprotectors are necessary in pathogenetic treatment of acute hepatitis B and C.